HALO · Halozyme Therapeutics, Inc.
$125.63
+0.88% last session
End-of-day data · close of 2026-10-23
Market cap
$14B
Enterprise value
$16B
Trailing P/E
36.7
Forward P/E
11.8
Dividend yield
0.0%
Beta
0.88
Avg volume
2M
Employees
0K
Daily Change %
0.88%
5 Days Change
2.22%
10 Days Change
13.61%
30 Days Change
10.76%
60 Days Change
14.64%
Month to Day Change
16.46%
Year to Day Change
85.05%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — HALO
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-13
Latest call per bank · past 12 months
JP Morgan
Neutral$78.00
-37.9% vs priceWells Fargo
Equal-Weight$95.00
-24.4% vs priceMorgan Stanley
Overweight$93.00
-26.0% vs priceGoldman Sachs
Neutral$56.00
-55.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Maintains | Buy | $105 → $130 |
| 2026-10-08 | JP Morgan | Maintains | Neutral | $70.00 → $78.00 |
| 2026-10-08 | HC Wainwright & Co. | Maintains | Buy | $115 → $130 |
| 2026-09-02 | HC Wainwright & Co. | Reiterates | Buy | $115 |
| 2026-08-08 | Leerink Partners | Upgrade | Market Perform → Outperform | $83.00 → $110 |
| 2026-08-07 | TD Cowen | Maintains | Buy | $96.00 → $105 |
| 2026-08-07 | Citizens | Maintains | Market Outperform | $92.00 → $93.00 |
| 2026-08-07 | Wells Fargo | Maintains | Equal-Weight | $75.00 → $95.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- bearish: RSI (14): RSI is 74 — overbought territory; the recent run-up may be due for a pause.
- bullish: Price vs 50-day MA: Trading 13.0% above the 50-day MA ($111.14).
- bullish: Price vs 200-day MA: Trading 53.3% above the 200-day MA ($81.94).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+1.10) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($125.63).
HALO Price Chart
Loading chart for HALO…
Fundamentals
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.